Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter...

Area of Science:

• Medical Oncology
• Immunotherapy
• Thoracic Oncology

Background:

• Advanced non-small-cell lung cancer (NSCLC) remains a significant challenge in oncology.
• First-line treatment options are continuously evolving to improve patient outcomes.
• Immune checkpoint inhibitors, like toripalimab, show promise in various cancers.

Purpose of the Study:

• To evaluate the efficacy and safety of toripalimab combined with chemotherapy as a first-line treatment for advanced NSCLC.
• To assess the impact of toripalimab on progression-free survival (PFS) and overall survival (OS).
• To explore potential predictive biomarkers for treatment response.

Main Methods:

• The CHOICE-01 study was a randomized trial involving 465 treatment-naive patients with advanced NSCLC (excluding EGFR/ALK mutations).
• Patients received either toripalimab plus chemotherapy or placebo plus chemotherapy for 4-6 cycles, followed by maintenance therapy.
• Primary endpoint was PFS; secondary endpoints included OS and safety. Genomic analysis was performed on tumor samples.

Main Results:

• Toripalimab significantly improved median PFS (8.4 vs. 5.6 months) and median OS (not reached vs. 17.1 months) compared to placebo.
• Adverse event rates were similar between arms, indicating a manageable safety profile.
• High tumor mutational burden and specific pathway mutations (focal adhesion-PI3K-Akt) were associated with improved PFS and OS in the toripalimab arm.

Conclusions:

• Toripalimab in combination with chemotherapy is an effective first-line treatment for advanced NSCLC, significantly enhancing PFS and OS.
• The combination therapy offers a favorable safety profile.
• The benefits were particularly pronounced in patients with nonsquamous NSCLC and those with specific genomic alterations.